• Shanshan Liu, Xiongwei Yu, Baoji Hu, Yun Zou, Jinbao Li, Lulong Bo, and Xiaoming Deng.
• Department of Anesthesiology and Intensive Care, Changhai Hospital, Second Military Medical University, Shanghai, China; Department of Anesthesiology, Chenggong Hospital, Xiamen University, Xiamen, China.
• J. Surg. Res. 2015 May 1;195(1):277-83.

BackgroundSalidroside (SDS) is the main effective component of Rhodiola rosea L with a variety of pharmacologic properties. The objective of this study was to investigate the efficacy of SDS in the treatment of experimental sepsis in mice and explore the possible underlying action mechanisms.MethodsSepsis was induced in C57BL/6 male mice via cecal ligation and puncture (CLP). The animals were divided into three groups as follows: sham, CLP, and CLP plus SDS. SDS (50 mg/kg) was injected intraperitoneally 1 h after operation. Postoperative survival of the mice, bacterial clearance in blood and peritoneal lavage fluid, cytokine secretion in blood, and histology of lung were evaluated. In addition, apoptosis of immune cells in the spleen and thymus were examined, respectively.ResultsSDS administration prolonged the survival of the septic mice, inhibited the proinflammatory responses, and enhanced bacterial clearance. It also alleviated the pathologic changes in the lung and inhibited the apoptosis of immune cells in the spleen and thymus after CLP challenge.ConclusionsSDS exerts a protective effect in CLP-induced sepsis by attenuating the proinflammatory responses, enhancing bacterial clearance, and preserving adaptive immunity. SDS may be a promising therapeutic strategy for the treatment of sepsis.Copyright © 2015 Elsevier Inc. All rights reserved.

39 keywords...

hide…